Drug Research
Lilly and Rigel collaborate to develop RIPK1 inhibitors for potential treatment of immunological and neurodegenerative diseases
Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant...
Drug Research
AstraZeneca, IDT To Ramp Up COVID-19 Vaccine Manufacturing In Europe
Following the European Medicines Agency (EMA) approval, millions of AstraZeneca vaccines began shipping on 5 February as part of the initial 17m doses that are due to be delivered over the next weeks, with more planned in March.
AstraZeneca and...
Drug Research
Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of...
Drug Research
Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
Avid Bioservices, Inc. and Humanigen, Inc. announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal...
Drug Research
Merck and BioNTech to boost lipid supply for Covid-19 vaccine production
Merck and BioNTech have announced a further expansion of their strategic partnership to accelerate the supply of urgently needed lipids and boost the amount of their delivery by the year-end.
The lipids will be used for producing the Pfizer and...
Drug Research
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.
GSK...
Drug Research
Abzena selected to develop and manufacture antibody cocktail for Immunome’s COVID-19 Antibody Based Treatment
Immunome, Inc., a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
